The drugs in question, which include an antidepressant and a diabetes medication, are being sold of as part of Teva’s compliance with anti-trust regulations. Teva will continue to manufacture the products on Watson’s behalf.
Watson CEO Paul Bisaro said: "These products represent a sound complement to our extensive generics portfolio," adding that they will have immediate impact on the company will begin to see a financial benefit in 2009.